⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 2, 2025Open Access

Supplementary Figure S1 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047

Evan J. Lipson Sonia Dolfi Hao Tang Hussein A. Tawbi Francisco Medina-Soto Erika Castillo Gutiérrez Piotr Rutkowski Helen Gogas E. de Eusebio Murillo Paolo A. Ascierto Keyur Desai Michele Maio Korey Demers Antonella Mazzei Sarah Keidel Karen Miller-Moslin Jia Xin Yu F. Stephen Hodi Dirk Schadendorf Georgina V. Long Charlie Garnett‐Benson

View Full Paper

Ask AI

Bookmark

Share

Key Points

On-treatment changes in CD8+ CM cells correlate with best overall response in advanced melanoma patients.
Alterations in CD4+ EM cell populations are also associated with patient outcomes, highlighting their importance.
Patients receiving relatlimab showed significant immune cell changes linked to treatment efficacy.
Insights from biomarker analyses may guide future therapeutic strategies for melanoma.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Observational analysis reveals associations of CD8+ CM and CD4+ EM cells with response in melanoma patients, indicating potential biomarkers.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lipson et al. (2025) studied this question.

synapsesocial.com/papers/68c182609b7b07f3a060f67d https://doi.org/10.1158/1078-0432.30029467

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S5 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
2Supplementary Figure S8 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
3Supplementary Figure S7 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
4Supplementary Figure S4 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
5Supplementary Figure S6 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025

Supplementary Figure S2 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
Supplementary Figure S3 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
Supplementary Figure 5 from Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair–Proficient Colorectal Cancer2025